Toronto, Ontario, January 29, 2015 / Theralase Technologies Inc. (“Theralase”) (TLT:TSXV) (TLTFF: OTC Pink(R)) announced today that its latest research on its lead Photo Dynamic Compound (“PDC“) TLD-1433 binding to transferrin has been accepted for presentation at the 15th International Photodynamic Association (“IPA“) / Society of Photo-Optical Instrumentation Engineers (“SPIE“) Biophotonics Conference taking place in Rio de Janeiro, Brazil from May 22 to 26, 2015. The IPA was founded in 1986. Its membership consists of the most prominent international clinicians and scientists involved in performing and researching Photo Dynamic Therapy (“PDT“) and Photo Diagnosis (“PD“). The purpose of the IPA is promote the study of diagnosis and treatment using light and PDCs, to disseminate such information to the members of the IPA, the medical community and to the general public. The IPA organises an International Congress every two years, which is a unique opportunity to sum up research activities in the … Read More

Toronto, Ontario – January 20, 2015, Theralase Technologies Inc. (“Theralase”)(TLT:TSXV) (TLTFF: OTC Pink®) announced today that it has filed a provisional US patent application for “Transferrin Enhanced Photo Dynamic Therapy (“PDT”) Cancer Destruction” significantly increasing the targeting of its PDT technology; hence, also the efficacy and safety of the treatment.” Transferrin is a substance that naturally occurs in the body (iron-binding blood plasma glycoprotein) that controls the level of free iron in our biological fluids. When transferrin encounters a transferrin receptor (“TfR”) on the surface of a cell, it is able to more effectively bind to that specific cell and delivery its payload, in this case Theralase’s lead Photo Dynamic Compound (“PDC”), TLD-1433. Overexpression of transferrin receptors for a variety of cancers has been scientifically documented and is attributed to the malignant transformation of normal cells into cancer cells. Theralase’s recent scientific research, which is the subject of this particular  … Read More

Toronto, Ontario – January 15, 2015, Theralase Technologies Inc. (“Theralase”) (TLT:TSXV) (TLTFF: OTC Pink®) announced today that it has identified its lead Photo Dynamic Compound (“PDC”) that it plans to enter into a Health Canada Clinical Trial Application (“CTA”) / Food and Drug Administration (“FDA”) Investigational New Drug (“IND”) Application for the destruction of Non Muscle Invasive Bladder Cancer (“NMIBC”) in 2015. The lead PDC has been identified to be TLD-1433, a Ruthenium based PDC that has demonstrated a high Therapeutic Ratio, which has the highest overall performance in the green and red laser light spectrums for multiple cancer cell lines, including glioma (primary brain tumours that originate from the supportive cells of the brain) and bladder cancer. The Therapeutic Ratio represents the ability of the PDC to destroy cancer cells by comparing cancer cell destruction in the absence of light (dark toxicity) to cancer cell destruction when light activated … Read More

Toronto, Ontario – January 13, 2015, Theralase Technologies Inc. (“Theralase”) (TLT:TSXV) (TLTFF: OTC Pink®) announced today that Roger Dumoulin-White, President and CEO of Theralase will present at the 2nd Annual AlphaNorth Capital Conference to be held at the Atlantis Resort on Paradise Island, Bahamas from January 16th to 18th, 2015. The 2nd Annual AlphaNorth Capital Conference in the Bahamas will feature some of the best small cap innovators in the technology, biotech, healthcare and special situations spaces and connect them with the top institutions and specialist brokers in North America through a full day series of one-on-one meetings between issuers and finance. Roger Dumoulin-White, President and CEO of Theralase stated that, “In 2015, one of Theralase’s key objectives is to introduce the Theralase story to new Canadian, US and international investors to allow them the opportunity to hear firsthand of our successes to date and the compelling reasons why investment … Read More

Toronto, Ontario – January 9, 2015, Theralase Technologies Inc. (“Theralase”) (TLT:TSXV) (TLTFF: OTC Pink®) announced today a summary of its 2014 scientific achievements published in peer reviewed, high impact scientific journals or presented at international conferences that detail its ongoing commitment to establishing the scientific and preclinical research required to support the launch of its cutting-edge technologies. In addition, Theralase confirms its 2015 strategic objectives with anticipated timing. From December 2013 to December 2014, the following peer reviewed papers have been published in high impact scientific journals or presented at international conferences and been globally recognized by the international scientific and medical community:   Photodynamic Inactivation of Staphylococcus aureus and Methicillin-Resistant Staphylococcus aureus with Ru(II)-based Type I/ Type II Photosensitizers (Photodiagnosis Photodynamic Therapy, 10(4):615-25, Dec. 2013) Theralase’s ability to destroy two types of bacteria (Staphylococcus aureus and Methicillin Resistant Staphylococcus aureus (MRSA)) up to 99.99999%, with a new class of … Read More

Toronto, Ontario – December 23, 2014, Theralase Technologies Inc. (“Theralase”)(TLT:TSXV) (TLTFF: OTC Pink®) announced today that it has obtained preliminary results from the use of Photo Dynamic Therapy (“PDT”) to destroy bladder cancer in an orthotopic (“occurring at the normal place in the body”) rat model. The University of Toledo in conjunction with the Princess Margaret Cancer Centre, University Health Network (“UHN”) and Theralase conducted the experiment in a well-established orthotopic model for bladder cancer in rats. Experiment: The rat bladder urothelium (inner lining) sustained localized injury via cauterization to allow adhesion of AY27 rat bladder cancer cells One of the lead Theralase Photo Dynamic Compounds (“PDCs”) (TLD1433) was infused into the bladder once the tumour had reached 1 mm by 1 mm in size (Dose equal to 1 mg of PDC / 20 ml of distilled water solution) After 60 minutes incubation, the PDC was removed from the bladder … Read More

Toronto, Ontario – December 16, 2014 Theralase Technologies Inc. (“Theralase”) (TLT:TSXV) (TLTFF: OTC Pink®) announced today that Brian C. Wilson, PhD has agreed to join the Theralase Medical and Scientific Advisory Board (“MSAB”). Dr. Wilson is a Senior Scientist and Head of the Applied Biophotonics group at Princess Margaret Cancer Centre, University Health Network and Professor in the Department of Medical Biophysics at the University of Toronto. The focus of the research of the Applied Biophotonics group is the development and application of new therapeutic and diagnostic techniques based on the use of lasers and other optical technologies. In this translational research, a wide range of methodologies are used: theoretical and experimental studies of light transport in tissues, development of light sources, development of optical-fiber light delivery devices and optical dosimeters, photobiological studies at the cellular and tissue level, in vivo optical spectroscopy of tissues, development of prototype clinical instruments … Read More

Toronto, Ontario – December 9, 2014 Theralase Technologies Inc. (“Theralase”) (TSXV: TLT) (TLTFF: OTC Pink®) announced today that the University of Toledo has conducted in-vitro Photo Dynamic Compound (“PDC”) experimentation that replicates preclinical results obtained earlier by Princess Margaret Cancer Centre, University Health Network (“UHN”), thus validating the Theralase PDC technology at two world renowned institutions. Theralase strategically partnered with the University of Toledo to confirm its in-vitro preclinical PDC results because of the expertise resident in the urology department led by Steve Selman, MD, FACS, Chair and Professor of Urology and Director of Urological Research, University of Toledo, Toledo, Ohio. Dr. Selman stated that, “I am pleased that we have been given the opportunity to work with Theralase and UHN on the preclinical validation of the Theralase PDC technology. The preclinical results we have obtained mirror the results obtained by UHN and thus provide Theralase the comfort that their … Read More

Toronto, Ontario – December 3, 2014 Theralase Technologies Inc. (“Theralase”) (TLT:TSXV) (TLTFF: OTC Link®) announced today that Michael A. O’Donnell, MD, Professor of Urology, University of Iowa located in Iowa City, Iowa has agreed to join the Theralase Medical and Scientific Advisory Board (“MSAB”). Dr. O’Donnell’s basic and clinical research has a long history of focusing on bladder immunology and bladder cancer immunotherapy, particularly the anti-cancer mechanisms of bacillus Calmette-Guerin (“BCG”) and its enhancement with combination therapies. Dr. O’Donnell recently headed a national trial of bladder cancer treatment utilizing BCG plus interferon (a natural protein which induces healthy cells to combat disease) comprised of over 1,000 patients and holds several U.S. patents for his work. While BCG has long been a standard treatment for bladder cancer, its toxicity profile can be devastating. Dr. O’Donnell’s studies, both laboratory and clinical, seek to both determine the exact mechanism by which BCG targets … Read More

Toronto, Ontario – December 2, 2014 Theralase Technologies Inc. (“Theralase”) (TLT:TSXV) (TLTFF: OTC Link®) announced today that Ashish M. Kamat, MD, MBBS, FACS, has agreed to join the Theralase Medical and Scientific Advisory Board (“MSAB”). Dr Kamat is an internationally recognized expert in urologic oncology and an authority in the management of urologic cancers. His expertise is with an emphasis on bladder cancer, organ sparing and minimally invasive techniques. Dr Kamat maintains an active research portfolio in this area with a focus on efforts to develop novel therapies, and identifying predictors of response to therapy (e.g. intravesical immunotherapy), as a first step towards personalized cancer therapeutics. He has initiated, led, and been active in several large studies including multinational trials in bladder cancer; these findings have been published in high impact journals. He is recognized internationally for his efforts and has been invited as a visiting professor to several universities … Read More